Empyema
Critical Alerts
- Empyema is a surgical infection - drainage is essential, not just antibiotics
- Delay in drainage worsens outcomes - early intervention improves survival
- Complicated parapneumonic effusion progresses to empyema without intervention
- Loculated effusions require specialty intervention (VATS, fibrinolytics)
- Consider empyema in any patient with pneumonia not responding to antibiotics
Key Diagnostics
- CT chest with contrast (best for loculations, staging)
- Diagnostic thoracentesis with pleural fluid analysis
- Pleural fluid criteria: pH <7.2, glucose <40 mg/dL, LDH >1000 IU/L, positive Gram stain/culture
- Blood cultures (often negative)
- Inflammatory markers (CRP, procalcitonin)
Emergency Treatments
- IV antibiotics: Empiric broad-spectrum coverage including anaerobes
- Chest tube drainage: Large bore (24-28 Fr) or image-guided small bore
- Cardiothoracic surgery consultation: For loculated disease, treatment failure
- Intrapleural fibrinolytics: TPA/DNase for loculated empyema
- Supportive care: Oxygen, fluids, nutrition
Empyema thoracis is defined as the presence of pus in the pleural space. It represents the end stage of a spectrum of pleural space infections that begins with simple parapneumonic effusion and progresses through complicated parapneumonic effusion to frank empyema. Early recognition and aggressive management are crucial for optimal outcomes.
Stages of Pleural Infection
| Stage | Duration | Characteristics | Drainage |
|---|---|---|---|
| Exudative | Days 1-3 | Free-flowing, sterile, low LDH | Usually resolves with antibiotics |
| Fibrinopurulent | Days 4-14 | Fibrin deposition, loculations, bacteria present | Drainage required |
| Organizing | Days 14+ | Pleural peel, trapped lung | May need decortication |
Classification
Simple Parapneumonic Effusion
- Sterile
- pH >7.2
- Glucose >60 mg/dL
- LDH <1000 IU/L
- Resolves with antibiotics alone
Complicated Parapneumonic Effusion
- pH <7.2 or
- Glucose <40 mg/dL or
- LDH >1000 IU/L or
- Positive Gram stain/culture
- Requires drainage
Empyema
- Frank pus in pleural space or
- Positive culture with biochemical markers
Epidemiology
- Incidence: 1-5% of patients hospitalized with pneumonia
- Mortality: 5-15% with treatment; higher in elderly, immunocompromised
- Risk factors: Diabetes, alcohol use, aspiration, poor dentition, immunosuppression
- Trends: Increasing incidence of methicillin-resistant Staph aureus (MRSA)
Development of Empyema
Parapneumonic Route (Most Common)
- Pneumonia with adjacent pleural inflammation
- Increased capillary permeability → exudative effusion
- Bacterial invasion of pleural space
- Neutrophil influx, fibrin deposition
- Loculation formation
- Pus accumulation (empyema)
- Fibroblast proliferation → pleural peel
Other Routes
- Direct extension from subdiaphragmatic infection
- Esophageal perforation
- Chest trauma or surgery
- Hematogenous seeding (rare)
Microbiology
Community-Acquired
| Organism | Frequency | Notes |
|---|---|---|
| Streptococcus pneumoniae | 40-50% | Most common in community |
| Oral anaerobes | 20-30% | Aspiration, poor dentition |
| Streptococcus milleri group | 15-25% | Propensity for abscess |
| Staphylococcus aureus | 10-15% | Including MRSA |
| Gram-negatives | 5-10% | Klebsiella, E. coli |
Hospital-Acquired/Post-Procedural
- Staphylococcus aureus (including MRSA)
- Gram-negative bacilli (Pseudomonas, Enterobacteriaceae)
- Polymicrobial (especially post-operative)
Special Populations
- Aspiration: Anaerobes predominate
- Immunocompromised: Fungi, mycobacteria, Nocardia
- IV drug use: S. aureus
Symptoms
| Symptom | Frequency | Description |
|---|---|---|
| Fever | 80-90% | Often persistent despite antibiotics |
| Cough | 70-80% | May be productive or dry |
| Pleuritic chest pain | 60-70% | Sharp, worse with breathing |
| Dyspnea | 50-70% | Proportional to effusion size |
| Weight loss | Common | Especially in chronic |
| Night sweats | Common | Suggest ongoing infection |
| Malaise/fatigue | Very common |
Signs
General
Chest Examination
| Finding | Significance |
|---|---|
| Decreased breath sounds | Effusion |
| Dullness to percussion | Fluid-filled pleural space |
| Reduced chest expansion | Splinting, effusion |
| Pleural friction rub | May precede effusion |
| Bronchial breathing | Above effusion level |
Clinical Scenarios
Typical Presentation
Subacute/Chronic Presentation
Acute Presentation
Critical Findings
| Red Flag | Concern | Action |
|---|---|---|
| Signs of sepsis/septic shock | Severe infection | Sepsis protocol, urgent drainage |
| Respiratory distress | Large effusion, respiratory failure | Urgent drainage, consider ICU |
| Tension physiology | Large effusion with mediastinal shift | Emergent drainage |
| Air-fluid level (lung abscess rupture) | Bronchopleural fistula | Surgical consultation |
| Bilateral empyema | Severe/disseminated infection | ICU admission |
| Immunocompromised host | Atypical organisms, poor outcome | Broad coverage, early intervention |
Indicators of Poor Prognosis
- Age >65 years
- Nosocomial acquisition
- Poor nutritional status
- Delayed drainage (>7 days from diagnosis)
- Loculated disease
- Positive blood cultures
- Renal impairment
- Low serum albumin
Causes of Exudative Pleural Effusion
| Condition | Distinguishing Features |
|---|---|
| Simple parapneumonic | pH >.2, resolves with antibiotics |
| Complicated parapneumonic | pH <7.2, needs drainage |
| Empyema | Frank pus, positive culture |
| Malignant effusion | Cytology positive, bloody, no response to antibiotics |
| Tuberculous effusion | Lymphocytic, elevated ADA, AFB stain/culture |
| Rheumatoid effusion | Very low glucose, high LDH |
| Chylothorax | Milky, high triglycerides |
| Hemothorax | Bloody, hematocrit >0% of serum |
Distinguishing Empyema from Other Effusions
Light's Criteria (Exudate if ANY met)
- Pleural protein / Serum protein >0.5
- Pleural LDH / Serum LDH >0.6
- Pleural LDH > 2/3 upper limit of serum normal
Empyema-Specific Criteria
- pH <7.2
- Glucose <40 mg/dL
- LDH >1000 IU/L
- Positive Gram stain or culture
- Frank pus
Clinical Assessment
Key History
- Duration and progression of symptoms
- Prior pneumonia and antibiotic treatment
- Risk factors for aspiration
- Prior chest procedures or thoracic surgery
- Dental health (anaerobic source)
Imaging
Chest X-ray
- May show pleural effusion (blunted costophrenic angle)
- Loculated effusions may appear as D-shaped densities
- May see consolidation suggesting underlying pneumonia
- Air-fluid level suggests bronchopleural fistula
CT Chest with Contrast (Gold Standard)
| Finding | Interpretation |
|---|---|
| Pleural enhancement (split pleura sign) | Active pleural infection |
| Loculations | Complicated effusion |
| Air bubbles in fluid | Bronchopleural fistula or gas-forming organisms |
| Thickened pleura | Organizing stage |
| Underlying consolidation | Pneumonia source |
| Mediastinal shift | Large effusion |
Ultrasound
- Excellent for guiding thoracentesis
- Can detect loculations and septations
- "Complex" appearance suggests complicated effusion
- Useful for small effusions
Thoracentesis
Indications
- Any new pleural effusion in setting of pneumonia
- Effusion >10mm on lateral decubitus or >25mm on CT
Fluid Analysis
| Test | Empyema Finding |
|---|---|
| Appearance | Purulent, turbid |
| pH | <7.2 |
| Glucose | <40 mg/dL |
| LDH | >000 IU/L |
| Protein | > g/dL |
| Cell count | Predominantly neutrophils |
| Gram stain | May be positive |
| Culture | May be positive (50-60%) |
Laboratory Studies
| Test | Purpose |
|---|---|
| Blood cultures | Identify causative organism (positive ~20%) |
| CBC | Leukocytosis, anemia of chronic disease |
| CRP/ESR | Inflammatory markers for monitoring |
| Procalcitonin | Bacterial infection marker |
| LFTs, renal function | Baseline for antibiotic dosing |
| Albumin | Nutritional status, prognosis |
Antibiotic Therapy
Empiric Regimens
| Setting | Regimen | Duration |
|---|---|---|
| Community-acquired | Ceftriaxone 2g IV + Metronidazole 500mg IV q8h | 2-4 weeks |
| Alternative | Ampicillin-sulbactam 3g IV q6h | 2-4 weeks |
| MRSA risk | Add Vancomycin 15-20mg/kg IV q8-12h | 2-4 weeks |
| Hospital-acquired | Piperacillin-tazobactam 4.5g IV q6h + Vancomycin | 2-4 weeks |
| Severe/ICU | Meropenem 1g IV q8h + Vancomycin | 2-4 weeks |
Duration
- Minimum 2-3 weeks IV therapy
- Consider PO step-down after clinical improvement and adequate drainage
- Total treatment often 4-6 weeks
Pleural Space Drainage
Indications for Drainage (Any of)
- Frank pus on thoracentesis
- pH <7.2
- Glucose <40 mg/dL
- Positive Gram stain or culture
- Loculated effusion on imaging
Drainage Options
| Method | Indication | Considerations |
|---|---|---|
| Small-bore catheter (12-14 Fr) | Free-flowing effusion, early disease | Image-guided placement |
| Large-bore chest tube (24-28 Fr) | Thick pus, traditional approach | May drain better in thick fluid |
| Intrapleural fibrinolytics | Loculated effusion | TPA 10mg + DNase 5mg BID x 3 days |
| VATS debridement | Failed drainage, thick septations | First-line surgical option |
| Thoracotomy/Decortication | Organizing stage, trapped lung | Major surgery, selected patients |
Chest Tube Management
- Place to 20 cmH2O suction
- Monitor output (expect high initially)
- Daily CXR to assess resolution
- Flush if blocked (10-20mL saline)
- Remove when output <100-150 mL/day and lung expanded
Intrapleural Fibrinolysis (MIST2 Trial Protocol)
Alteplase (TPA) 10 mg in 30 mL NS +
Dornase alpha (DNase) 5 mg in 30 mL NS
Administration:
- Dose TPA via chest tube, clamp 1 hour
- Then dose DNase, clamp 1 hour
- Then open to suction
- Repeat BID for 3 days (6 doses of each)
Evidence: Reduces hospital stay, need for surgery
Surgical Intervention
Indications for Surgery
- Failed chest tube drainage after 5-7 days
- Multiple loculations not responding to fibrinolytics
- Thick pleural peel (organizing stage)
- Necrotizing pneumonia with bronchopleural fistula
- Underlying malignancy requiring diagnosis
Surgical Options
| Procedure | Description |
|---|---|
| VATS debridement/decortication | Minimally invasive, effective in fibrinopurulent stage |
| Open thoracotomy/decortication | For thick peel, failed VATS |
| Open window thoracostomy | For failed decortication, chronically ill patients |
ICU Admission Criteria
- Sepsis or septic shock
- Respiratory failure requiring high-flow O2 or ventilation
- Need for emergent drainage
- Hemodynamic instability
- Significant comorbidities requiring monitoring
Hospital Ward Admission
- All patients with empyema require admission
- Hemodynamically stable patients
- Post-chest tube placement observation
- IV antibiotic therapy
Transfer Considerations
- Transfer to facility with cardiothoracic surgery if unavailable
- Complex/refractory cases may need specialized center
Discharge Criteria
- Afebrile for 48+ hours
- Chest tube removed, lung expanded on CXR
- Tolerating oral antibiotics
- Stable or improving inflammatory markers
- Follow-up arranged
Outpatient Follow-up
| Timeframe | Purpose |
|---|---|
| 1-2 weeks | Clinical assessment, labs, CXR |
| 4-6 weeks | CXR to confirm resolution |
| 3 months | Final assessment, CT if concern for residual |
Understanding Empyema
- Empyema is an infection in the space around the lung
- It usually develops from pneumonia
- Treatment requires both antibiotics and drainage
- Recovery takes several weeks
Chest Tube Care
- The tube drains infected fluid from your chest
- It will be attached to a collection device
- Report pain, difficulty breathing, or tube dislodgement
- Keep insertion site clean and dry
Recovery Expectations
- Hospital stay typically 1-2 weeks or longer
- Fatigue may persist for weeks to months
- Gradual return to normal activity
- Complete antibiotic course is essential
Warning Signs After Discharge
- Fever returning
- Worsening shortness of breath
- Increasing chest pain
- Drainage from chest tube site
- Feeling unwell/deteriorating
Immunocompromised Patients
- Higher risk for atypical organisms (fungi, mycobacteria, Nocardia)
- May present with minimal symptoms
- Broader empiric coverage needed
- Consider early surgical consultation
Elderly Patients
- Higher mortality rates
- Often delayed presentation
- More comorbidities complicating management
- May require extended hospitalization
Post-Surgical/Traumatic Empyema
- Often S. aureus or Gram-negatives
- May have resistant organisms
- Early surgical involvement
- Consider possibility of esophageal injury
Tuberculous Empyema
- Chronic presentation (weeks to months)
- Lymphocytic predominant fluid
- Elevated adenosine deaminase (ADA)
- Requires anti-tuberculous therapy
- May need surgical decortication
Pediatric Considerations
- S. pneumoniae and S. aureus most common
- More likely to develop empyema from CAP than adults
- Often respond well to fibrinolytics
- Generally better outcomes than adults
Performance Indicators
| Metric | Target |
|---|---|
| CT imaging for suspected empyema | >0% |
| Thoracentesis performed if indicated | >5% |
| Drainage initiated within 24h of diagnosis | >0% |
| Appropriate empiric antibiotics | >5% |
| Cardiothoracic surgery consultation for drainage failure | 100% |
Documentation Requirements
- Pleural fluid analysis results
- Imaging findings (loculations, size)
- Drainage method and output
- Antibiotic regimen and duration plan
- Response to treatment
- Disposition rationale
Diagnostic Pearls
- Suspect empyema in any pneumonia not improving on antibiotics
- CT is gold standard for assessing loculations and guiding intervention
- pH <7.2 requires drainage - don't wait for culture
- Split pleura sign on contrast CT indicates active pleural infection
- Think of anaerobes in aspiration-related cases
Treatment Pearls
- Antibiotics alone are insufficient - drainage is essential
- Earlier drainage = better outcomes
- Small bore catheters work if free-flowing
- TPA/DNase combination reduces surgery need in loculated disease
- Don't delay surgery if drainage fails after 5-7 days
Disposition Pearls
- All empyema requires admission - no outpatient management
- CT before discharge is not always needed if clinically resolved
- Oral step-down after at least 1 week IV and clinical improvement
- Follow-up CXR at 4-6 weeks to confirm resolution
- Smoking cessation counseling for all
- Davies HE, et al. Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65 Suppl 2:ii41-53.
- Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection (MIST2 trial). N Engl J Med. 2011;365(6):518-526.
- Shen KR, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153(6):e129-e146.
- Colice GL, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest. 2000;118(4):1158-1171.
- Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174(7):817-823.
| Version | Date | Changes |
|---|---|---|
| 1.0 | 2025-01-15 | Initial comprehensive version with 14-section template |